Pulmonx Secures $40M Debt Facility with Perceptive, Repays Old Loan, Reports Mixed Q1 Results
LUNG sits 18% above its 52-week low of $1.13.
Summary
Pulmonx Corp refinanced its debt, securing $40 million from a new facility with Perceptive, which is critical for liquidity despite high interest and warrant dilution. Q1 results showed a revenue decline but improved net loss and operating cash flow.
Key Events · Financing and Capital Events · LUNG
-
Debt Refinancing Completed
The company repaid its entire $37.2 million CIBC Loan and drew an initial $40.0 million from a new $60.0 million senior secured term loan facility with Perceptive Credit Holdings V, LP on March 2, 2026. This follows the new debt facility with warrants mentioned in the 10-K filed on 2026-03-10.
-
High Cost of Capital and Potential Dilution
The new Perceptive Loan carries a high annual effective interest rate of 13.9%. Additionally, Pulmonx issued warrants to purchase up to 1,000,000 shares of common stock at an exercise price of $1.92 per share, with an option for an additional 500,000 shares if further tranches are drawn. This represents a potential dilution of approximately 3.55% if all warrants are issued and exercised.
-
Q1 2026 Financial Performance
Revenue decreased by 8.7% year-over-year to $20.6 million for the three months ended March 31, 2026, primarily due to a lack of sales into China. However, net loss improved to $(13.7) million from $(14.4) million in Q1 2025, and net cash used in operating activities decreased to $(10.1) million from $(13.2) million in the prior year period.
-
Liquidity and Going Concern
As of March 31, 2026, the company had cash and cash equivalents of $61.6 million. Management believes this, along with the new debt facility, will allow the company to continue its planned operations for at least the next 12 months.
Analysis · LUNG · Industrial Applications And Services
Pulmonx Corp has completed a significant debt refinancing, securing crucial liquidity for its operations. The company repaid its entire $37.2 million CIBC Loan and drew an initial $40.0 million from a new $60.0 million senior secured term loan facility with Perceptive Credit Holdings V, LP. This new facility comes with an annual effective interest rate of 13.9% and includes the issuance of warrants to purchase up to 1,000,000 shares of common stock, with potential for an additional 500,000 shares. While this financing provides a vital cash runway, the high cost of capital and potential dilution from warrants reflect the company's challenging financial position. The Q1 2026 financial results show a year-over-year revenue decline of 8.7% to $20.6 million, but an improvement in net loss and operating cash flow, indicating some operational efficiency gains. Management believes existing cash and equivalents will fund operations for at least the next 12 months.
At the time of this filing, LUNG was trading at $1.33 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $56.2M. The 52-week trading range was $1.13 to $3.89. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.